Comment
Author: Admin | 2025-04-27
First Opinion Charles M. Silver, David A. Hyman, and Michael F. Cannon The health policy cult’s misplaced faith in government First Opinion W. Craig Vanderwagen and Jennifer B. Alton STAT Plus: HHS’ national health security division must be preserved advertisement First Opinion Erin McConnell, Kendall Martinez-Wright, and Lizzy Lovinger The Kansas City TB outbreak shows the value of U.S. government health funding First Opinion Chris Gibson STAT Plus: Recursion CEO: Publicly funded research built the biopharma industry. Now it needs our help First Opinion Denis Nash The ‘disease detectives’ dodged a bullet — but another might be coming First Opinion Ariel Reinish What my sister’s life and death taught me about the NIH First Opinion Ruth R. Faden and Nancy Kass The abrupt end of USAID-funded clinical trials is profoundly unethical First Opinion Joseph J. Fins STAT Plus: A physician and author’s 1984 tribute to the NIH feels all the more valuable today First Opinion Maya Gottfried The doctor indicted by Louisiana for prescribing abortion pills saved my life Letters to the editor Dennis J. Selkoe There is no ‘amyloid cabal’ in Alzheimer’s research First Opinion Daniel X. Pham The FDA must remove an unnecessary barrier to the use of clozapine for treatment-resistant schizophrenia First Opinion Atul Grover and Megan L. Ranney How to close America’s life expectancy gap First Opinion Christopher Morten, Ben Anderson, Charles Duan, Gregg Gonsalves, Cynthia M. Ho, Amy Kapczynski, Jordan Paradise, Reshma Ramachandran, Joseph S. Ross, Michael S. Sinha, Anthony D. So, Liza Vertinsky, and Kiran Zelbo STAT Plus: Gilead’s short-term win threatens the future of pharmaceutical public-private partnerships First Opinion Holden Thorp Science editor-in-chief Holden Thorp’s advice for other scientists with autism First Opinion Eric Reinhart Health workers face a stark choice: become collaborators or resisters First Opinion Charles Piller — Science How the ‘amyloid mafia’ took over Alzheimer’s research First Opinion Arjun Sharma Stopgap measures against H5N1 bird flu can only go so far First Opinion Noël Theodosiou and Yogi Hendlin STAT Plus: The life sciences industry needs a new approach First Opinion Diana M. Zuckerman and John H. Powers III The FDA’s misguided thinking on antibiotics First Opinion Carrie Wolinetz STAT Plus: Indirect research costs are complicated, wonky — and crucial to science First Opinion Harlan M. Krumholz STAT Plus: The NIH’s drastic cut to indirect cost rates is a critical threat to U.S. research infrastructure
Add Comment